ARQT (Arcutis Biotherapeutics) Beginning Cash Position: $35.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARQT Arcutis Biotherapeutics Inc ARQT
56 GF Score
Price $25.13
GF Value $30.59
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Arcutis Biotherapeutics Beginning Cash Position?

Arcutis Biotherapeutics ARQT -0.91% 56 Beginning Cash Position is $35.1 Mil as of Jun. 2026. GuruFocus rates ARQT with a GF Score™ of 56/100 and a GF Value™ of $30.59 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Arcutis Biotherapeutics's Beginning Cash Position for the quarter that ended in Jun. 2026 was $35.1 Mil.

Arcutis Biotherapeutics's quarterly Beginning Cash Position declined from Dec. 2025 ($47.4 Mil) to Mar. 2026 ($43.2 Mil) and declined from Mar. 2026 ($43.2 Mil) to Jun. 2026 ($35.1 Mil).

Arcutis Biotherapeutics's annual Beginning Cash Position increased from Dec. 2023 ($54.9 Mil) to Dec. 2024 ($89.3 Mil) but then declined from Dec. 2024 ($89.3 Mil) to Dec. 2025 ($72.0 Mil).

Arcutis Biotherapeutics Beginning Cash Position Related Terms

Arcutis Biotherapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Arcutis Biotherapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcutis Biotherapeutics Beginning Cash Position Chart

Arcutis Biotherapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 66.62 97.99 54.88 89.32 71.95

Arcutis Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.72 73.05 47.43 43.22 35.07
ARQT
56GF Score
Arcutis Biotherapeutics Inc ARQT
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcutis Biotherapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $35.1 Mil mean?
Arcutis Biotherapeutics (ARQT) has a Beginning Cash Position of $35.1 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arcutis Biotherapeutics and its competitors.
Is Arcutis Biotherapeutics' Beginning Cash Position too high?
Arcutis Biotherapeutics' current Beginning Cash Position is $35.1 Mil. Overall, Arcutis Biotherapeutics has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arcutis Biotherapeutics' Beginning Cash Position compare to IDYA and NAMS?
Arcutis Biotherapeutics' Beginning Cash Position of $35.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arcutis Biotherapeutics and its competitors. Arcutis Biotherapeutics's current Beginning Cash Position is $35.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcutis Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arcutis Biotherapeutics (ARQT) is currently considered Modestly Undervalued. The stock's GF Value™ is $30.59, compared to a current price of $25.13 — trading 17.8% below its estimated fair value. The current Beginning Cash Position is $35.1 Mil. Arcutis Biotherapeutics' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Arcutis Biotherapeutics (ARQT), the current Beginning Cash Position is $35.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcutis Biotherapeutics (ARQT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcutis Biotherapeutics stock appears to be undervalued. The current stock price of $25.13 is trading 17.8% below its estimated GF Value™ of $30.59. GuruFocus considers Arcutis Biotherapeutics to be Modestly Undervalued.

Key valuation signals for ARQT:

  • Beginning Cash Position: $35.1 Mil
  • GF Value™: $30.59 vs. price of $25.13 (17.8% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ARQT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcutis Biotherapeutics Business Description

Address 3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
56GF Score

Get the complete analysis for ARQT

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.13
Price
$30.59
GF Value